Table 3.

Comparison of IQWiG assessment and G-BA decision for new medicines regarding presence of additional benefit

	IQWiG	G-BA
Abiraterone acetate	+	+
Aliskiren/amlodipine	−	−
Apixaban	+	+
Azilsartan medoxomil	n.d.	−
Belatacept	+	+
Belimumab	−	+
Boceprevir	+	+
Bromfenac	n.d.	−
Cabazitaxel	+	+
Emtricitabine/rilpivirine/tenofovir disoproxil	−	+
Eribulin	−	+
Extract of Cannabis sativa	−	+
Fampridine	−	−
Fingolimod	+	+
Ipilimumab	+	+
Linagliptin	−	−
Microbial collagenase	−	−
Pirfenidone	−	+
Pitavastatin	n.d.	−
Regadenoson	n.d.	−
Retigabine	−	−
Rilpivirine	+	+
Tafamidis meglumine	n.d.	+
Telaprevir	+	+
Ticagrelor	+	+
Vandetanib	−	−
Vemurafenib	+	+

In case of different subgroups within an EBA, the best subgroup assessment was used

Information on http://www.g-ba.de/informationen/nutzenbewertung/ in manufacturers’ dossier and G-BA decision

+, additional benefit; −, no additional benefit; n.d., not determined